Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

• Main Authors: San-Miguel, J, Bladé, J, Shpilberg, O, Grosicki, S, Maloisel, F, Min, C.-K, Zarzuela, M.P, Robak, T, Prasad, S.V.S.S, Goh, Y.T, Laubach, J, Spencer, A, Mateos, M.-V, Palumbo, A, Puchalski, T, Reddy, M, Uhlar, C, Qin, X, Van De Velde, H, Xie, H, Orlowski, R.Z
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: American Society of Hematology 2020
• Subjects: antivirus agent; bisphosphonic acid derivative; bortezomib; immunoglobulin A; interleukin 6; melphalan; prednisone; siltuximab; add on therapy; adult; aged; anemia; article; bleeding; bone disease; bronchopneumonia; chromosome 17p; drug efficacy; drug fatality; drug response; drug safety; gastrointestinal disease; herpes zoster; human; hypokalemia; incidence; infection; leukocytoclastic vasculitis; maintenance therapy; major clinical study; multicenter study; multiple myeloma; neuralgia; neutropenia; overall survival; peripheral neuropathy; phase 2 clinical trial; pneumonia; priority journal; progression free survival; radius fracture; respiratory failure; sensory neuropathy; septic shock; suicide; thrombocytopenia; very elderly; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183894
• Institution: National University of Singapore

10.1182/blood-2013-12-546374